Biosimilars are a prescription for better health.
Biosimilars could lead to over $54 billion in savings over the next ten years, giving 1.2 million patients access to needed medicines.
This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market.
Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.
These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.